Amarantus BioSciences, Inc. (“Amarantus”) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.
The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards an prolonged life expectancy due to novel therapies and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses a critical unmet medical need: safely and effectively improving currently-approved patients treatments.
Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies
President & CEO Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was
promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research
collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as
Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong
co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe,
Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and
executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a
Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the
Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering
with a focus Financial Decisions from Stanford University.
John W. Commissiong, PhD
Chief Scientific Officer Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2009.
From 2000 through 2008 Dr. Commissiong served as the CSO of Neurotrophics Inc & Prescient Neuropharma Inc. Dr. Commissiong
has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as
understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was
Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic
approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where
he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific
Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently
in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to
significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding
of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-
related disorders. Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of
quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of
Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry
from the University of the West Indies.
Marc E. Faerber
Controller / Chief Financial Officer Controller Mr. Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned
Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing
financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology,
gastroenterology, orthopedics, diagnostics and biotechnology. Mr. Faerber has extensive transactional experience, including considerable experience in establishing international
organizations throughout Europe and parts of Asia, international technology licensing and distribution transactions, mergers
and acquisitions, and numerous funding transactions, including an initial public offering as well as other international
business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management
including CFO, CEO and Director. Mr. Faerber started his career working for KPMG, is a certified public accountant, and has a
Bachelor of Sciences in Business Administration from Providence College.
AMBS PR Dec/01/11 Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA) 120th Investment Conference
SUNNYVALE, Calif., Dec 01, 2011 (BUSINESS WIRE) -- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease--modifying therapeutic protein, today announced that it has been selected to present at 120th National Investment Banking Association's Conference in Las Vegas, NV at Caesar's Palace on Thursday, December 1st at 10:10am Pacific. NIBA is the only national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8000 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.
NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, and give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure, collectively voice their positions on issues impacting the securities industry, and enhance their knowledge and expertise through ongoing education programs designed to enable them to remain competitive in today's financial market.
EVENT INFORMATION AT A GLANCE:
WHO: Gerald Commissiong, President and Chief Executive Officer WHEN: November 30, 2011 - December 2, 2011 WHERE: Caesars Palace Las Vegas Hotel & Casino- 3570 Las Vegas Blvd South, Las Vegas, NV
About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.